FDA Adverse Event Injury Summary report: N

INTRALASE FS2

MDR report key: 2970044 · Received February 20, 2013

Report

Report Number
3006695864-2013-00054
Event Type
Injury
Date Received
February 20, 2013
Date of Event
December 9, 2012
Report Date
January 21, 2013
Manufacturer
ABBOTT MEDICAL OPTICS
Product Code
HNO
PMA / PMN Number
K060372
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NE, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

(B)(4) -ON (B)(4) 2013, CUSTOMER REPORTED THE OUTCOME FOR THE STAGE 1 DLK CASES. (B)(4): PLACEHOLDER.

Additional Manufacturer Narrative · 1

EVALUATION CONCLUSION: - THE EQUIPMENT WAS NOT EVALUATED AFTER THE TREATMENT DATE WHICH OCCURRED ON (B)(6) 2012, DUE TO THE FACT ABBOTT MEDICAL OPTICS (AMO) BECAME AWARE ON (B)(6) 2013. THE CONDITION OF THE SYSTEM (SINCE THE TIME OF THE EVENT) WILL MAKE THE EVALUATION IMPOSSIBLE. THE CLINIC REPORTED THIS EVENT ONLY AND DID NOT REQUEST FIELD SERVICE OR CLINICAL SUPPORT. AMO'S CLINICAL DEVELOPMENT MANAGER (CDM) CONTACTED THE CUSTOMER. CDM INFORMED THE CUSTOMER THAT USE OF A GENERIC STEROID DROPS INCREASES THE RISK OF DLK. PLACEHOLDER.

Description of Event or Problem · 1

CUSTOMER REPORTED 2 CASES OF STAGE 1 DIFFUSE LAMELLAR KERATITIS (DLK). PATIENT HAD DLK ON THE RIGHT EYE (OD). CUSTOMER TREATED PATIENT WITH PREDNISOLONE ACETATE DROPS. UNCORRECTED VISUAL ACUITY (VA) ON (B)(6) 2012, OD WAS 20/15. ON (B)(6) 2012, CUSTOMER REPORTED THE OUTCOME FOR THE STAGE 1 DLK CASES. DATE OF SURGERY WAS PERFORMED ON (B)(6) 2012, FOR BOTH PATIENTS. DLK WAS NOTICED ON (B)(6) 2012, FOR BOTH PATIENTS. DLK WAS RESOLVED ON BOTH PATIENTS ON (B)(6) 2012. PRED FORTE 1% WAS USED TO TREAT DLK FOR BOTH PATIENTS. NO LOSS IN VISION; BEST CORRECTED VISUAL ACUITY (BCVA) WAS 20/20 PRE- AND POST-OPERATIVELY FOR BOTH PATIENTS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
74166 INTRALASE FS2 FEMTOSECOND LASER HNO ABBOTT MEDICAL OPTICS 20005D

Patients

Seq Age Sex Outcome Treatment
1 24 YR Other